Cyagen Closes $41 Million Series B to Expand Animal Research Model Business
publication date: Feb 26, 2020
Cyagen Biosciences Suzhou closed a $41 million Series B financing that it will use to expand its genetically modified rodent business. The round included investments from funds managed by CMS Capital, two GF Securities entities and Guanghua Investment. Founded in 2011, Cyagen claims to be the world's largest provider of custom-engineered mouse and rat models, offering transgenic, knockout, knock-in, CRISPR, and ES-cell based models. It also offers a comprehensive series of stem cell products for research use, including cell lines, media and differentiation kits. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.